User login
Treatment for moderate to severe active ulcerative colitis (UC) has evolved, and with more effective treatment comes higher standards for disease control.
The initial goal is clinical response, followed by clinical remission, endoscopic remission, and — the ultimate goal — histologic remission.
The majority of UC medications have been studied for clinical and endoscopic remission. Recent clinical trials, however, have evaluated the emerging targeted therapies ustekinumab and ozanimod for histologic remission and found positive results.
Dr Bincy Abraham, director of the Fondren Inflammatory Bowel Disease Program at Houston Methodist in Houston, Texas, reports on UC treatment milestones and how emerging targeted therapies can help achieve these goals.
She also discusses patient monitoring to ensure response to therapy as well as medication adjustments should response prove inadequate.
--
Professor of Clinical Medicine, Department of Internal Medicine and Gastroenterology; Director, Fondren Inflammatory Bowel Disease Program, Underwood Center for Digestive Disorders, Houston Methodist, Houston, Texas
Bincy Abraham, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; BMS; Janssen; Pfizer; Takeda; Medtronic
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; BMS; Janssen; Pfizer; Takeda
Received research grant from: Takeda; BMS; Genentech
Treatment for moderate to severe active ulcerative colitis (UC) has evolved, and with more effective treatment comes higher standards for disease control.
The initial goal is clinical response, followed by clinical remission, endoscopic remission, and — the ultimate goal — histologic remission.
The majority of UC medications have been studied for clinical and endoscopic remission. Recent clinical trials, however, have evaluated the emerging targeted therapies ustekinumab and ozanimod for histologic remission and found positive results.
Dr Bincy Abraham, director of the Fondren Inflammatory Bowel Disease Program at Houston Methodist in Houston, Texas, reports on UC treatment milestones and how emerging targeted therapies can help achieve these goals.
She also discusses patient monitoring to ensure response to therapy as well as medication adjustments should response prove inadequate.
--
Professor of Clinical Medicine, Department of Internal Medicine and Gastroenterology; Director, Fondren Inflammatory Bowel Disease Program, Underwood Center for Digestive Disorders, Houston Methodist, Houston, Texas
Bincy Abraham, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; BMS; Janssen; Pfizer; Takeda; Medtronic
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; BMS; Janssen; Pfizer; Takeda
Received research grant from: Takeda; BMS; Genentech
Treatment for moderate to severe active ulcerative colitis (UC) has evolved, and with more effective treatment comes higher standards for disease control.
The initial goal is clinical response, followed by clinical remission, endoscopic remission, and — the ultimate goal — histologic remission.
The majority of UC medications have been studied for clinical and endoscopic remission. Recent clinical trials, however, have evaluated the emerging targeted therapies ustekinumab and ozanimod for histologic remission and found positive results.
Dr Bincy Abraham, director of the Fondren Inflammatory Bowel Disease Program at Houston Methodist in Houston, Texas, reports on UC treatment milestones and how emerging targeted therapies can help achieve these goals.
She also discusses patient monitoring to ensure response to therapy as well as medication adjustments should response prove inadequate.
--
Professor of Clinical Medicine, Department of Internal Medicine and Gastroenterology; Director, Fondren Inflammatory Bowel Disease Program, Underwood Center for Digestive Disorders, Houston Methodist, Houston, Texas
Bincy Abraham, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; BMS; Janssen; Pfizer; Takeda; Medtronic
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; BMS; Janssen; Pfizer; Takeda
Received research grant from: Takeda; BMS; Genentech
